Direct alpha-adrenergic stimulation of hepatic glucose production in human subjects.
Six normal humans each underwent infusions of 1) saline; 2) propranolol; 3) somatostatin; 4) somatostatin with propranolol; and 5) somatostatin with propranolol plus phentolamine on separate occasions. Propranolol alone had no effect on glucose production or plasma glucose. Somatostatin alone produced the expected initial decrease followed by an increase in both hepatic glucose production and plasma glucose. beta-Adrenergic blockade with propranolol displaced the glucose production (MANOVA, P = 0.0220) and plasma glucose (MANOVA, P = 0.0057) somatostatin response curves to higher levels, whereas alpha-adrenergic blockade with phentolamine combined with beta-adrenergic blockade displaced the glucose production (MANOVA, P = 0.0281) and plasma glucose (MANOVA, P = 0.0134) somatostatin response curves to lower levels. Because plasma insulin, C-peptide, and glucagon were suppressed comparably under all three conditions and plasma glucose concentrations were comparable initially, this represents direct alpha-adrenergic stimulation of hepatic glucose production in postabsorptive humans demonstrable when the primary glucoregulatory hormones are withdrawn and beta-adrenergic mechanisms are blocked. It is best attributed to sympathetic neural norepinephrine release.
D000328:Adult; D000704:Analysis of Variance; D001786:Blood Glucose / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D004347:Drug Interactions; D005260:Female; D005943:Gluconeogenesis / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008099:Liver / Q000378:metabolism*; D008297:Male; D010646:Phentolamine; D011433:Propranolol; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D013004:Somatostatin
D001786:Blood Glucose; D011942:Receptors, Adrenergic, alpha; D013004:Somatostatin; D011433:Propranolol; D010646:Phentolamine